[PDF][PDF] Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
G Hess, R Herbrecht, J Romaguera… - Journal of Clinical …, 2009 - researchgate.net
G Hess, R Herbrecht, J Romaguera, G Verhoef, M Crump, C Gisselbrecht, A Laurell, F Offner…
Journal of Clinical Oncology, 2009•researchgate.netPurpose Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, has
shown clinical activity in mantle cell lymphoma (MCL). We evaluated two dose regimens of
temsirolimus in comparison with investigator's choice single-agent therapy in relapsed or
refractory disease.
shown clinical activity in mantle cell lymphoma (MCL). We evaluated two dose regimens of
temsirolimus in comparison with investigator's choice single-agent therapy in relapsed or
refractory disease.
Purpose
Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, has shown clinical activity in mantle cell lymphoma (MCL). We evaluated two dose regimens of temsirolimus in comparison with investigator’s choice single-agent therapy in relapsed or refractory disease.
researchgate.net